At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
APRE Aprea Therapeutics, Inc.
Pre-Market Trading 03-12 05:11:11 EDT
2.45
+0.22
+9.87%
| High2.76 | Low2.30 | Vol86.43K |
| Open2.76 | D1 Closing2.23 | Amplitude20.63% |
| Mkt Cap13.32M | Tradable Cap9.75M | Total Shares5.43M |
| T/O219.87K | T/O Rate2.17% | Tradable Shares3.98M |
| P/B-- | ROE-- | EPS0.00 |
| 52wk High-- | 52wk Low-- | P/E-- |
| Dividend-- | Div.Yield-- | ROA-- |
Loading ...
BRIEF-Aprea Therapeutics Announces Agreement With MD Anderson Cancer Center To Explore Apr-1051 As A Potential Treatment For Head And Neck Squamous Cell Carcinoma (Hnscc)
Reuters · 03-11 14:15
Aprea Therapeutics provides update on existing patent portfolio
TipRanks · 02-06
Aprea Therapeutics Announces Strategic Ip Portfolio Evolution in DNA Damage Response (Ddr) Cancer Therapeutics
THOMSON REUTERS · 02-05
BRIEF-Aprea Therapeutics Announces Twice Daily (Bid) Dosing Of Patients In ABOYA-119 Clinical Trial Of ATRN-119 To Potentially Optimize Clinical Outcomes
Reuters · 2024-12-11
Aprea Therapeutics announces first patient dosed in ABOYA-119 Phase 1/2a trial
TIPRANKS · 2024-12-11
Aprea Therapeutics- Dose Escalation in Aboya-119 Trial Expected to Continue With Both Once-Daily & Twice-Daily Dosing Schedules
THOMSON REUTERS · 2024-12-11
Aprea Therapeutics Announces Twice Daily (Bid) Dosing of Patients in Aboya-119 Clinical Trial of Atrn-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward
THOMSON REUTERS · 2024-12-11
Aprea Therapeutics Inc -Anticipates Phase 1 Readout in Second Half of 2025
THOMSON REUTERS · 2024-12-11
Aprea Therapeutics Price Target Maintained With a $20.00/Share by HC Wainwright & Co.
Dow Jones · 2024-11-18
BRIEF-Aprea Therapeutics - Got Into At The Market Offering Agreement, May Offer & Sell Shares Of Common Stock Of Up To $3 Million From Time To Time - SEC Filing
Reuters · 2024-11-08
Aprea Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Reuters · 2024-11-08
Aprea Therapeutics Inc: Cash Runway for at Least Twelve Months
THOMSON REUTERS · 2024-11-07
Aprea Therapeutics Q3 Net Income USD -3.8 Million
THOMSON REUTERS · 2024-11-07
Insider Spends US$132k Buying More Shares In Aprea Therapeutics
Simply Wall St. · 2024-10-23
Insider Spends US$132k Buying More Shares In Aprea Therapeutics
Aprea Therapeutics presents preliminary results on APR-1051
TIPRANKS · 2024-10-23
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
GlobeNewswire · 2024-09-20
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
Life Sciences Virtual Investor Forum Agenda Announced for September 19th
GlobeNewswire · 2024-09-16
Life Sciences Virtual Investor Forum Agenda Announced for September 19th
Introduction
Company Name.
Aprea Therapeutics, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.
Issue price:
--
Invest in Global Markets with Tiger Brokers!Open App